![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Agilis’s AGIL-FA Gets Orphan Drug Designation
Agilis’s AGIL-FA Gets Orphan Drug Designation
The FDA has granted orphan drug designation for Agilis’s gene therapy candidate AGIL-FA.
The product is being developed to treat the degenerative neuromuscular disorder Friedreich’s ataxia.
Agilis says it is the first company to receive orphan drug designation from the FDA for a gene therapy to treat the condition.
Upcoming Events
-
21Oct